These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2574044)

  • 21. The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
    Saunders E
    Am Heart J; 1991 Sep; 122(3 Pt 2):936-42. PubMed ID: 1678925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine.
    Mulvihill-Wilson J; Gaffney FA; Pettinger WA; Blomqvist CG; Anderson S; Graham RM
    Circulation; 1983 Feb; 67(2):383-93. PubMed ID: 6129077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic effects of terazosin in congestive heart failure.
    Zhu J; Wang D; Lu Z; Liu Z; Yang D
    Chin Med Sci J; 1993 Jun; 8(2):98-100. PubMed ID: 7904837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term experience with terazosin for treatment of mild to moderate hypertension.
    Mersey JH
    Am J Med; 1986 May; 80(5B):68-72. PubMed ID: 2872810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hemodynamic and clinical responses to terazosin, a new alpha blocking agent, in congestive heart failure.
    Leier CV; Patterson SE; Huss P; Parrish D; Unverferth DV
    Am J Med Sci; 1986 Sep; 292(3):128-35. PubMed ID: 2875651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
    Strom JA; Zola B; Frishman W; Laddu A; Wexler JP; Carlson K; Jordan A
    Am Heart J; 1991 Sep; 122(3 Pt 2):892-900. PubMed ID: 1678919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of terazosin.
    Kyncl JJ
    Am J Med; 1986 May; 80(5B):12-9. PubMed ID: 2872801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
    Somberg JC; Achari R; Laddu AR
    Am Heart J; 1991 Sep; 122(3 Pt 2):901-5. PubMed ID: 1678920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rest and exercise cardiovascular effects of terazosin in congestive heart failure.
    Magorien RD; Sinnathamby S; Leier CV; Boudoulas H; Unverferth DV
    Am J Cardiol; 1990 Mar; 65(9):638-43. PubMed ID: 1968703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
    Pasanisi F; Imperatore G; Vaccaro O; Iovine C; Ferrara LA
    Nutr Metab Cardiovasc Dis; 1999 Apr; 9(2):73-7. PubMed ID: 10726112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall safety of terazosin as an antihypertensive agent.
    Sperzel WD; Glassman HN; Jordan DC; Luther RR
    Am J Med; 1986 May; 80(5B):77-81. PubMed ID: 2872812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension.
    Lytle T; Coles S; Waite MA
    J Hum Hypertens; 1991 Feb; 5(1):35-8. PubMed ID: 1674964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of terazosin as an antihypertensive agent.
    Luther RR; Glassman HN; Jordan DC; Sperzel WD
    Am J Med; 1986 May; 80(5B):73-6. PubMed ID: 2872811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.
    Vincent J; Dachman W; Blaschke TF; Hoffman BB
    J Clin Invest; 1992 Nov; 90(5):1763-8. PubMed ID: 1358918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of terazosin on blood pressure and serum lipids.
    Gong P; Tang J; Cheng L; Lu Z; Zhang J; Zeng F
    J Tongji Med Univ; 1999; 19(4):291-4. PubMed ID: 12938521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.